Compare DECK & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DECK | WST |
|---|---|---|
| Founded | 1973 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 20.2B |
| IPO Year | 1993 | N/A |
| Metric | DECK | WST |
|---|---|---|
| Price | $99.74 | $279.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 10 |
| Target Price | $121.63 | ★ $346.78 |
| AVG Volume (30 Days) | ★ 3.5M | 661.6K |
| Earning Date | 10-23-2025 | 10-23-2025 |
| Dividend Yield | N/A | ★ 0.31% |
| EPS Growth | ★ 18.83 | 0.17 |
| EPS | 6.75 | ★ 6.75 |
| Revenue | ★ $5,244,323,000.00 | $3,017,900,000.00 |
| Revenue This Year | $9.84 | $7.01 |
| Revenue Next Year | $7.36 | $6.20 |
| P/E Ratio | ★ $14.77 | $41.51 |
| Revenue Growth | ★ 12.62 | 4.92 |
| 52 Week Low | $78.91 | $187.43 |
| 52 Week High | $223.98 | $348.90 |
| Indicator | DECK | WST |
|---|---|---|
| Relative Strength Index (RSI) | 67.87 | 55.28 |
| Support Level | $81.40 | $269.08 |
| Resistance Level | $86.09 | $285.54 |
| Average True Range (ATR) | 3.00 | 7.15 |
| MACD | 2.31 | 1.29 |
| Stochastic Oscillator | 99.97 | 82.62 |
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2025, Ugg and Hoka accounted for 51% and 45% of total sales, respectively. The firm also markets niche brands Teva and Ahnu. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has nearly 200 company-operated stores. It generated 64% of its fiscal 2025 sales in the United States.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.